S-1360 Shionogi-GlaxoSmithKline.
Shionogi and GlaxoSmithKline, as the joint venture company Shionogi-GlaxoSmithKline Pharmaceuticals, is developing S-1360, an HIV integrase inhibitor as a potential treatment for HIV infection. As of October 2002, phase II trials were ongoing and launch is expected in 2004/2005.
Billich
Andreas
A
Novartis Research Institute, PO Box 80, Brunner Strasse 59, 1235 Vienna, Austria. billich@pharma.novartis.com
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D019428:HIV Integrase Inhibitors / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D014230:Triazoles
D019380:Anti-HIV Agents; D005663:Furans; D019428:HIV Integrase Inhibitors; C451733:S 1360; D014230:Triazoles